GTB-3650 for High-Risk MDS and Relapsed/Refractory AML
This study is testing a new treatment called GTB-3650 for adults with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) that has come back or not responded to previous treatments. You might be able to join if you are 18 or older, have one of these conditions, and meet specific blood count requirements. GTB-3650 is given as a continuous infusion (IV drip). The main goal of this study is to find the safest and most effective dose of GTB-3650. This is a Phase 1 study, meaning it's an early stage of testing. The study is currently recruiting 45 participants.
- Study design
- This is a Phase 1 study designed to find the right dose of GTB-3650. It plans to enroll 45 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint, which measures the maximum tolerated dose, is assessed at 6 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT06594445
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
Recruiting
PHASE1Ages 18+InterventionalTreatmentMasonic Cancer Center, University of MinnesotaInvestigator-initiated
~45 participants
Updated 2026-07-14 on ClinicalTrials.gov
What's tested:GTB-360
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
MTD (ug/kg/day)
Measured over 6 months
Conditions
Where it's being run
1 sites across 1 statesMinnesota1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Diagnosis of a high risk myelodysplastic syndromes (MDS), treatment related MDS, OR relapsed/refractory acute myelogenous leukemia (AML).
Absolute lymphocyte count (ALC) ≥ 200 cells/µL OR absolute circulating CD56+/CD3- NK cell count \>25 cells/µL within the 14 days prior to Cycle 1 Day 1.
Peripheral blasts ≤20,000 at the time of treatment start. Hydroxyurea may be used up to Day 1 of the 1st cycle to achieve this threshold and continued for the 1st two weeks of Cycle 1 to maintain it.
Karnofsky performance status ≥ 70%
Adequate organ function within 14 days (30 days for cardiac) of Cycle 1 Day 1
Sexually active persons of childbearing potential or persons with partners of childbearing potential must agree to use a highly effective form of contraception during study treatment and for at least 4 months after the last dose of GTB-3650. Non-childbearing is defined as \>1 year postmenopausal or surgically sterilized.
For the Dose Finding Component Only: Must agree to stay within a 60- minute drive of the Study Center through the Cycle 1 Day 29 visit (end of the Dose Limiting Toxicity period).
Provides voluntary written consent prior to the performance of any research related activity.
Pulmonary: room air 0 2 saturation at ≥ 95%
Exclusion
Pregnant or breast-feeding. The effect of GTB-3650 TriKE on the fetus is unknown. Persons of childbearing potential must have a negative serum or urine test within 7 days prior to Cycle 1 Day 1 to rule out pregnancy.
A candidate for hematopoietic stem cell transplant (HSCT) or newly relapsed after HSCT (e.g. no post-HSCT therapy given).
Bi-phenotypic acute leukemia or mixed lineage leukemia.
Acute promyelocytic leukemia (APL).
No anticancer therapy within 14 days of Cycle 1 Day 1; any AEs from therapy given prior must have resolved to Grade 1 or baseline
New or progressive pulmonary infiltrates on screening chest x-ray or chest CT scan unless cleared for study by Pulmonary. Infiltrates attributed to infection must be stable/improving with associated clinical improvement after 1 week of appropriate therapy (4 weeks for presumed or documented fungal infections).
Active systemic infection requiring parenteral antibiotic therapy. Any prior systemic infections must have resolved following optimal therapy.
Known history of HIV.
Active Hepatitis B or Hepatitis C (virus detectable by PCR) - chronic asymptomatic viral hepatitis is allowed.
Positive test results from chronic hepatitis B infection (defined as positive HBsAg serology) and/or positive test results for hepatitis C (HCV antibody serology test).
Prior malignancy except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer currently in complete remission, or any other cancer from which the patient has been disease-free for 1 year
Active central nervous system (CNS) malignancy or symptoms of CNS spread or administration of IT chemotherapy within 14 days prior to Day 1.
Extramedullary disease causing symptoms and/or involving the CNS or spinal canal - asymptomatic extramedullary disease outside the CNS and spinal canal is eligible provided the marrow has measurable disease.
Known autoimmune disease requiring active treatment with steroids or other immunosuppressive medications within 14 days before Cycle 1 Day. Inhaled or topical steroids, and adrenal replacement steroid doses ≤ 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
Persons with a condition requiring systemic treatment with steroids (\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days before Cycle 1 Day 1.
The potential risk of QT/QTc prolongation is unknown in humans receiving
QTc interval \> 480 msec at screening
A family history of long QT syndrome
Psychiatric illness/social situations that, in the judgement of the enrolling Investigator, would limit compliance with study requirements.
Other illness or a medical issue that, in the judgement of the enrolling Investigator, would exclude the patient from participating in this study.
What this trial measures
- MTD (ug/kg/day)6 months
Maximum tolerated dose (MTD) of GTB-3650 TriKE defined as the dose level that most closely corresponds to the target dose limiting toxicity (DLT) proportion of 20% or less.